Open AccessThe correlation between vascular endothelial growth factor and prostate cancer with and without metabolic syndrome
Author(s) -
Yanan Zhou,
Jingyu Song,
Gang-Liang Tu,
Hui Xu,
Meng Ding
Publication year - 2021
Publication title -
nepalese journal of cancer
Language(s) - English
Resource type - Journals
eISSN - 2594-3308
pISSN - 2594-3294
DOI - 10.3126/njc.v5i1.41410
Subject(s) - medicine , prostate cancer , vascular endothelial growth factor , body mass index , blood pressure , triglyceride , malignancy , endocrinology , metabolic syndrome , cancer , oncology , urology , cholesterol , obesity , vegf receptors
Objective: To investigate the relationship between vascular endothelial growth factor (VEGF), metabolic syndrome and its components and degree of differentiation of prostate cancer. Methods: The clinical data of 49 PCa cases treated during October, 2018 to February, 2021 were retrospectively analyzed, including patients’ height, weight, body mass index (BMI), age, blood pressure (BP), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), fasting blood glucose (FBG), vascular endothelial growth factor (VEGF) and Gleason score. Results: Compared with simple PCa group, BMI, the MS group had higher BMI, diastolic blood pressure (DBP, FGB, TG) and VEGF (P<0.05), and higher Gleason score (P<0.05). MS group had a higher degree of malignancy (Gleason≥8). Conclusion: This suggests that MS may promote the progression of PCa, and the increase of VEGF level can indicate the presence of MS in PCa patients, reflecting the progression of PCa to a certain extent.